Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Powers

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Journal of Cancer Survivorship : Research and Practice|January 14, 2017
Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivorsHeather Spencer Feigelson, Carmit K McMullen, Sarah Madrid, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2007
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitorsWenge Zhong, Hu Liu, Matthew R Kaller, et al.
Bioorganic & Medicinal Chemistry|August 19, 2007
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitorsRobert M Rzasa, Matthew R Kaller, Gang Liu, et al.
American Journal of Epidemiology|May 16, 2024
Current use of estrogen-containing oral contraceptives or hormone therapy and risk of COVID-19 infection and hospitalization: a population-based cohort studyLaura B Harrington, J David Powers, Elizabeth A Bayliss, et al.
JCO Clinical Cancer Informatics|November 1, 2023
Development of an Electronic Health Record-Based Algorithm for Predicting Lung Cancer Screening Eligibility in the Population-Based Research to Optimize the Screening Process Lung Research ConsortiumAndrea N Burnett-Hartman, J David Powers, Brian P Hixon, et al.
Alaska Medicine|April 21, 2005
Guidelines for the management of head injuries in remote and rural AlaskaFrank Sacco, Ken Zafren, Ken Brown, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonistsNing Xi, Stephen Arvedson, Shawn Eisenberg, et al.
Journal of Diabetes and Its Complications|May 5, 2015
Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM Project, 2005-2011Emily B Schroeder, J David Powers, Patrick J O'Connor, et al.
Journal of Medicinal Chemistry|January 15, 2015
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK)Adrian L Smith, Kristin L Andrews, Holger Beckmann, et al.
Molecular Cancer Therapeutics|August 10, 2004
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancerDaniel E H Afar, Vinay Bhaskar, Eric Ibsen, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Journal of Cancer Survivorship : Research and Practice|January 14, 2017
Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivorsHeather Spencer Feigelson, Carmit K McMullen, Sarah Madrid, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2007
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitorsWenge Zhong, Hu Liu, Matthew R Kaller, et al.
Bioorganic & Medicinal Chemistry|August 19, 2007
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitorsRobert M Rzasa, Matthew R Kaller, Gang Liu, et al.
American Journal of Epidemiology|May 16, 2024
Current use of estrogen-containing oral contraceptives or hormone therapy and risk of COVID-19 infection and hospitalization: a population-based cohort studyLaura B Harrington, J David Powers, Elizabeth A Bayliss, et al.
JCO Clinical Cancer Informatics|November 1, 2023
Development of an Electronic Health Record-Based Algorithm for Predicting Lung Cancer Screening Eligibility in the Population-Based Research to Optimize the Screening Process Lung Research ConsortiumAndrea N Burnett-Hartman, J David Powers, Brian P Hixon, et al.
Alaska Medicine|April 21, 2005
Guidelines for the management of head injuries in remote and rural AlaskaFrank Sacco, Ken Zafren, Ken Brown, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonistsNing Xi, Stephen Arvedson, Shawn Eisenberg, et al.
Journal of Diabetes and Its Complications|May 5, 2015
Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM Project, 2005-2011Emily B Schroeder, J David Powers, Patrick J O'Connor, et al.
Journal of Medicinal Chemistry|January 15, 2015
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK)Adrian L Smith, Kristin L Andrews, Holger Beckmann, et al.
Molecular Cancer Therapeutics|August 10, 2004
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancerDaniel E H Afar, Vinay Bhaskar, Eric Ibsen, et al.
Pageof 9